Pharma tariff threat tests Roche US investment ambitions
Roche is considering its options in the US
Keystone / Dominik Pluess
Select your language
Generated with artificial intelligence.
Listening: Pharma tariff threat tests Roche US investment ambitions
Swiss pharmaceutical firm Roche could reconsider investing billions of dollars in the United States after President Donald Trump's pledge to lower medication costs.
Roche and Novartis have both recently announced huge US investments, partly in the hope of gaining goodwill from Trump’s administration. But the US is now targeting substantial price reductions on medications.
“If the proposed executive order goes into effect, the significant investments in the US we previously announced would be put to the test,” said a Roche spokesperson, confirming a report in the Neue Zürcher Zeitung.
A little over a month ago, Novartis announced it would invest $23 billion in additional factories and research laboratories in the US over the next five years. Roche plans to spend $50 billion on capacity expansion over the same period.
Trump’s executive order has instructed the US Department of Health and Human Services to begin negotiations with pharmaceutical companies within the next 180 days.
The department is expected to compile a list of benchmark prices within the next 30 days. If the manufacturers don’t lower the prices themselves, the Trump administration will attempt to do so through legislation.
More
More
Trump’s promise to lower drug prices rattles Swiss pharma stocks
This content was published on
US President Trump wants to make medicines cheaper in the US, which could mean huge losses for drugmakers, including those in Switzerland.
We select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication. Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
Did you find this explanation helpful? Please fill out the short survey below to help us understand your needs.
External Content
Popular Stories
More
Demographics
How retiring baby boomers could crash Swiss property market
This content was published on
Swiss politicians from across the political spectrum have called on the government to protect minorities in the face of continuing attacks in Syria.
Swiss court rejects appeal to release funds linked to former Ukraine regime
This content was published on
Swiss Supreme Court rejects appeal to unfreeze the assets of people linked to former Ukrainian President Viktor Yanukovych.
Sahara sand clouds Swiss visibility after Canadian smoke
This content was published on
Sahara dust has further clouded visibility in Swiss skies, adding to smoke particles that drifted over from forest fires in Canada.
Nuclear weapons spending exceeded $100 billion for first time
This content was published on
Spending by the nine nuclear powers topped the $100 billion mark for the first time last year, according to the NGO ICAN.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.